交易 UroGen Pharma Ltd. - URGN 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.13
• 長倉隔夜倉息調整: -0.02149%
• 短倉隔夜倉息調整: -0.00074%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 5.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 18.58
• 開倉: 18.26
• 1 年變化: 37.81%
• 日區間: 17.48 - 18.58

UroGen Pharma Ltd. (NASDAQ: URGN) is a clinical-stage biopharmaceutical company developing therapies for urothelial cancers and urologic diseases using its proprietary RTGel platform. The company’s lead asset, Jelmyto, is approved for low-grade upper tract urothelial cancer and serves as proof of concept for localized drug delivery. With additional candidates in bladder cancer, UroGen offers investors targeted exposure to niche oncology indications with a novel delivery mechanism.